Tag Archives: Rintega

March, 2016

  • 7 March

    Celldex Discontinues its Late-Stage Brain Cancer Vaccine Study

    HAMPTON, N.J., March 07, 2016 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the independent Data Safety and Monitoring Board (DSMB) has determined, based on a preplanned interim analysis, that continuation of the Phase 3 ACT IV study of RINTEGA® (rindopepimut) in patients with newly diagnosed EGFRvIII-positive glioblastoma …

June, 2015

  • 1 June

    Celldex Vaccine Improves Survival in Patients with Deadly Brain Cancer

    Celldex Therapeutics presented results showing that its investigational cancer vaccine helped extend the lives of patients with a deadly form of brain cancer. The company presented results from the mid-stage trial evaluating Rintega (rindopepimut) in patients with EGFRvIII-positive, recurrent glioblastoma at the 2015 American Society of Clinical Oncology (ASCO) Annual …